Vescap1 gm

Vescap is a highly purified ethyl ester of eicosapentaenoic acid (EPA) used in the management of triglyceride disorders and cardiovascular risk reduction. Its approved and evidence-based uses are classified below by strength of evidence.

Established / Approved Uses

• Cardiovascular risk reduction (adjunct therapy): Vescap is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina in adults with elevated triglyceride levels (≥150 mg/dL) who have established cardiovascular disease, or diabetes mellitus with two or more additional cardiovascular risk factors.
• Severe hypertriglyceridemia: Vescap is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (triglycerides ≥500 mg/dL).

Important Notes

• Vescap must always be used together with dietary modification and, where indicated, maximally tolerated statin therapy — it is not a substitute for these measures.
• Vescap is not indicated for weight loss, general cardiovascular prevention in the absence of the specific risk factors above, or as a first-line lipid-lowering agent.

Each soft gelatin capsule contains Icosapent Ethyl (a highly purified ethyl ester of eicosapentaenoic acid, EPA) as the active ingredient, typically available in 0.5 gram and 1 gram capsule strengths. Capsules also contain inactive ingredients used in softgel formulation.

Vescap is an omega-3 fatty acid derivative — specifically a highly purified and stable ethyl ester form of eicosapentaenoic acid (EPA), a naturally occurring polyunsaturated fatty acid. Unlike many over-the-counter fish oil products that combine EPA and DHA, Vescap contains essentially no DHA, which distinguishes its lipid effect profile (notably, it does not raise LDL-cholesterol the way some mixed omega-3 products can).

Vescap is supplied as an oral soft gelatin capsule and is used long-term as part of a comprehensive strategy to lower triglycerides and reduce cardiovascular risk in appropriately selected adult patients.

Vescap belongs to the therapeutic class of omega-3 fatty acid derivatives (antihyperlipidemic / triglyceride-lowering agents), used adjunctively for lipid management and cardiovascular risk reduction.

The precise mechanism by which Icosapent Ethyl reduces triglyceride levels and cardiovascular risk is not fully established. Proposed mechanisms include:

• Reduction of hepatic very-low-density lipoprotein (VLDL) triglyceride synthesis and/or secretion.
• Enhanced clearance of triglyceride-rich lipoproteins from the circulation, potentially via increased lipoprotein lipase activity and decreased apolipoprotein C-III.
• Additional proposed anti-inflammatory, antioxidant, membrane-stabilizing, and antithrombotic effects that may contribute to the observed reduction in cardiovascular events, independent of its triglyceride-lowering effect.

In a large cardiovascular outcomes trial, Icosapent Ethyl added to statin therapy significantly reduced the composite risk of major adverse cardiovascular events compared with placebo, an effect considered to extend beyond simple triglyceride reduction.

Take Vescap capsules by mouth twice daily with food. Swallow capsules whole; do not break, crush, dissolve, or chew them.

The following clinically significant interaction has been well established for Vescap:

• Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel, heparin, NSAIDs): Vescap, like other omega-3 fatty acid products, may prolong bleeding time. Concurrent use increases the risk of bleeding, and patients on these combinations should be monitored periodically for signs of bleeding.

No clinically significant cytochrome P450-mediated drug interactions have been well established for Vescap to date.

The most commonly reported side effects of Vescap in clinical trials include:

• Musculoskeletal pain
• Peripheral edema (swelling, usually of the legs/ankles)
• Constipation
• Gout
• Atrial fibrillation or atrial flutter (see Precautions)
• Arthralgia (joint pain)
• Oropharyngeal pain
• Bleeding events (see Precautions)

Patients should seek prompt medical attention for palpitations, irregular heartbeat, unusual bruising or bleeding, or any severe or persistent adverse effect while taking Vescap.

Pregnancy

Data on the use of Vescap in pregnant women are limited. Animal reproduction studies have not shown clear dose-related harm at clinically relevant exposures, but human data are insufficient to establish safety. Vescap should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use in pregnancy.

Lactation

Omega-3 fatty acids, including EPA, have been detected in human breast milk. There is limited information on the effects of Vescap on the breastfed infant or on milk production. A physician should be consulted to weigh the benefits of breastfeeding against any potential risk before using Vescap while breastfeeding.

The following precautions apply to the use of Vescap:

• Atrial fibrillation/flutter: Vescap has been associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, particularly in patients with a prior history of these arrhythmias or other significant cardiovascular conditions. Patients should be monitored for symptoms such as palpitations, irregular heartbeat, or shortness of breath.
• Bleeding risk: Vescap may increase the risk of bleeding, particularly in patients also taking anticoagulant or antiplatelet medications, or who have an underlying bleeding disorder. Monitor for signs of bleeding or bruising (see Interactions).
• Hepatic function: Periodic monitoring of liver function is advisable during long-term therapy, particularly in patients with pre-existing hepatic impairment.
• Allergy considerations: Because Vescap is derived from fish sources, patients with known fish or shellfish allergy should use it with caution and discuss the specific product source with their physician.

There is limited clinical experience with overdose of Vescap. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center right away. Management should be supportive and symptomatic, guided by a physician or emergency medical personnel; no specific antidote is known.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric patients: Safety and efficacy of Vescap have not been established; not recommended for use in children.
• Elderly patients: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients in clinical trials, but elderly patients often have more comorbidities and concomitant medications, so use with routine clinical monitoring.
• Renal impairment: No specific dose adjustment is established; use with routine monitoring (see Dosage and Administration).
• Hepatic impairment: Use with caution in patients with severe hepatic impairment, as this population has not been specifically studied (see Dosage and Administration).

Vescap is generally intended for long-term, ongoing use as part of ongoing cardiovascular risk reduction or triglyceride management, with the need for continued therapy periodically reassessed by the prescribing physician based on lipid response and clinical status.

Omega-3 fatty acid derivatives; Antihyperlipidemic agents; Triglyceride-lowering agents

Icosapent Ethyl is thought to lower triglycerides by reducing hepatic synthesis/secretion of VLDL-triglycerides and enhancing clearance of triglyceride-rich lipoproteins from circulation; additional anti-inflammatory and antithrombotic effects are proposed to contribute to its cardiovascular risk-reducing benefit, independent of triglyceride lowering alone.

The safety and efficacy of Vescap in pediatric patients have not been established. Its use is therefore not recommended in children and adolescents.